Novo Nordisk's positive trial results for a weight loss drug have propelled it ahead of Tesla in market value. GLP-1 drugs, including Wegovy, are sparking discussions on obesity treatment and their impact on food preference. The potential for weight-loss drugs to address various diseases is being explored, with a focus on their broader therapeutic applications. Concerns are raised about the marketing and impact of such drugs, with warnings about potential misuse and market exploitation, particularly in regions like China with rising obesity rates.
"Demand for weight-loss solutions is high in #China, where obesity rates among Chinese adults have more than doubled the past 2 decades...The % of adults classified as overweight & obese in π¨π³ reached 50.7% in 2022" https://t.co/D5DDR5yLbx
A tsunami of obesity drugs are in clinical trials ππ Cc: @rtnarch @Noahpinion @PeterDiamandis @DKThomp https://t.co/qm5KCEVQ1U
Could weight-loss drugs eat the world? Scientists are finding that anti-obesity medicines can also help treat many other diseases https://t.co/YFIEzhcPAB
PSA- Ozempic is the next opioid crisis. First we make everyone obese and pre-diabetic. Then we promote a miracle drug to fix it. Then Medicare funnels billions to Big Pharma, who use the $ to bribe doctors and regulatory agencies. Rinse, repeat. Huge target market. Beware. https://t.co/3vKwoS4PNa
Le Roux's group speculates about the next phase of GLP-1RA research: how the drugs will impact food preference and eating behavior, which has major implications for Big Industry. https://t.co/NGDroVehJD
Opinion: Oprah kicked off a national conversation on obesity and GLP-1 drugs. Letβs have it. https://t.co/m4AvXDudkF
Novo Nordisk eclipses Tesla on positive trial results for a weight loss drug that may be more powerful than its own Wegovy. https://t.co/ifGxfM9DsF